tiprankstipranks
Advertisement
Advertisement

TVTX Stock Latest News

Travere Therapeutics Signals Strong Growth in Earnings Call
Company AnnouncementsTravere Therapeutics Signals Strong Growth in Earnings Call
17d ago
TVTX
Travere Therapeutics price target raised to $68 from $49 at Piper Sandler
PremiumThe Fly
Travere Therapeutics price target raised to $68 from $49 at Piper Sandler
20d ago
TVTX
Travere Therapeutics price target raised to $78 from $68 at Evercore ISI
PremiumThe Fly
Travere Therapeutics price target raised to $78 from $68 at Evercore ISI
27d ago
TVTX
Travere Therapeutics price target raised to $75 from $61 at Wedbush
PremiumThe Fly
Travere Therapeutics price target raised to $75 from $61 at Wedbush
1M ago
TVTX
Travere Therapeutics price target raised to $70 from $62 at Canaccord
PremiumThe Fly
Travere Therapeutics price target raised to $70 from $62 at Canaccord
1M ago
TVTX
Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships
PremiumCompany AnnouncementsRegulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships
1M ago
TVTX
Travere Therapeutics price target raised to $68 from $60 at Evercore ISI
Premium
The Fly
Travere Therapeutics price target raised to $68 from $60 at Evercore ISI
1M ago
TVTX
Travere Therapeutics price target raised to $75 from $60 at TD Cowen
Premium
The Fly
Travere Therapeutics price target raised to $75 from $60 at TD Cowen
1M ago
TVTX
Travere Therapeutics price target raised to $75 from $65 at Guggenheim
PremiumThe Fly
Travere Therapeutics price target raised to $75 from $65 at Guggenheim
1M ago
TVTX
Travere Therapeutics price target raised to $62 from $43 at Stifel
PremiumThe Fly
Travere Therapeutics price target raised to $62 from $43 at Stifel
1M ago
TVTX
Travere Therapeutics price target raised to $85 from $70 at Citi
PremiumThe Fly
Travere Therapeutics price target raised to $85 from $70 at Citi
1M ago
TVTX
Travere Therapeutics: Buy Rating Reiterated as FILSPARI Momentum Builds and Key Catalysts Approach; Price Target Unchanged at $67
PremiumRatings
Travere Therapeutics: Buy Rating Reiterated as FILSPARI Momentum Builds and Key Catalysts Approach; Price Target Unchanged at $67
1M ago
TVTX
Closing Bell Movers: SpaceX slips after first quarterly report as public company
PremiumThe FlyClosing Bell Movers: SpaceX slips after first quarterly report as public company
1M ago
CC
AMD
Travere Therapeutics reports Q2 adjusted EPS (10c), consensus (14c)
Premium
The Fly
Travere Therapeutics reports Q2 adjusted EPS (10c), consensus (14c)
1M ago
TVTX
TVTX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
TVTX Upcoming Earnings Report: What to Expect?
1M ago
TVTX
Travere Therapeutics price target raised to $62 from $56 at Canaccord
PremiumThe Fly
Travere Therapeutics price target raised to $62 from $56 at Canaccord
1M ago
TVTX
Travere Therapeutics, Inc. (TVTX) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Travere Therapeutics, Inc. (TVTX) Q2 Earnings Cheat Sheet
1M ago
TVTX
Travere Therapeutics price target raised to $64 from $59 at BofA
PremiumThe Fly
Travere Therapeutics price target raised to $64 from $59 at BofA
2M ago
TVTX
Analyst Maintains Buy Rating on Travere as Updated Filspari Outlook and DCF Support Unchanged $60 Price Target
PremiumRatings
Analyst Maintains Buy Rating on Travere as Updated Filspari Outlook and DCF Support Unchanged $60 Price Target
2M ago
TVTX
Travere Therapeutics plans accounting leadership transition in 2026
PremiumCompany AnnouncementsTravere Therapeutics plans accounting leadership transition in 2026
2M ago
8K
TVTX
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
Premium
The Fly
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
2M ago
TVTX
Travere Therapeutics price target raised to $61 from $55 at Wedbush
Premium
The Fly
Travere Therapeutics price target raised to $61 from $55 at Wedbush
3M ago
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >